Look back at pharma news for the two weeks to December 31

31 December 2017

2017 ended with a couple of significant acquisitions stories: Roche’s $1.7 billion deal to buy Ignyta and Mallinckrodt’s $1.2 billion purchase of Sucampo Pharmaceuticals. There was also a flurry of year-end activity from the US Food and Drug Administration, which granted early approval for Aerie Pharmaceuticals’ glaucoma drug Rhopressa, as well as approvals for Exelixis’ cabozantinib and for Merck & Co and Pfizer’s Steglatro. Also attracting attention was Orchard Therapeutics’ fund raising.

Roche acquires a stake in the TRK field

The Ignyta deal gives Roche access to entrectinib, one of several highly promising tyrosine kinase inhibitors currently being investigated in trials for tumors harboring NTRK or ROS1 fusions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK